POTENTIAL RISKS OF PROPRANOLOL IN TREATMENT OF INFANTILE HEMANGIOMA Reply to: From the American Academy of Pediatrics:Clinical Report: Diagnosis and Management of Infantile Hemangioma David H. Darrow, Arin K. Greene, Anthony J. Mancini, Amy J. Nopper, and the SECTION ON DERMATOLOGY, SECTION ON OTOLARYNGOLOGY–HEAD AND NECK SURGERY, and SECTION ON PLASTIC SURGERY Pediatrics 2015; 136:4 e1060-e1104; published ahead of printSeptember 28, 2015, doi:10.1542/peds.2015-2485 POTENTIAL RISKS OF PROPRANOLOL IN TREATMENT OF INFANTILE HEMANGIOMA Arturo Tozzi, pediatrician ASL NA2 NORD, NAPLES -PEDIA3 Raffaele Minella The paper is very interesting, however it does not keep into account the very recent suggestions (1), which raise concerns about the potential long-term neurodevelopmental effects of the highly lipophilic propranolol. Indeed, blockage of neural pathways critical for memory and learning could be an unrecognized long-term side effect of such a drug (2). 1) Tozzi A. Oral Propranolol for Infantile Hemangioma N Engl J Med 2015; 373:284-285July 16, 2015DOI: 10.1056/NEJMc1503811 2) Hoeger PH. Propranolol for infantile haemangiomas: certain chances, potential risks. Br J Dermatol. 2015 Jan;172(1):3-4. doi: 10.1111/bjd.13535.